Original Articles
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases

CD48 AS A NOVEL EARLY BIOMARKER COMPLEMENTING PROCALCITONIN AND LACTATE FOR PREDICTING BACTEREMIA IN PEDIATRIC FEBRILE NEUTROPENIA: A PROSPECTIVE COHORT STUDY

CD48 A NOVEL EARLY BIOMARKER PREDICTING BACTERIEMIA

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: October 9, 2025
Accepted: December 19, 2025
Published: January 1, 2026
105
Views
49
Downloads
12
HTML

Authors

Background: Febrile neutropenia (FN) remains a frequent and potentially life-threatening complication in pediatric oncology, where prompt recognition of bacteremia is critical for risk-adapted therapy and antimicrobial stewardship. Traditional biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) are widely used, yet their early predictive value is inconsistent across studies. Cellular activation markers measured by flow cytometry, particularly CD48, have been scarcely investigated in this setting. This study aimed to evaluate conventional, metabolic, and immune biomarkers for predicting bacteremia in children with FN and to assess the incremental diagnostic value of CD48.

Methods:This prospective single-center cohort enrolled 38 pediatric oncology patients presenting with 46 FN episodes over nine months. Clinical data, blood cultures, and serial measurements of CRP, PCT, lactate, interleukin-6, interleukin-8, MCP-1, sTREM-1, CD48, and CD64 were obtained at 0, 24, 48, and 72 hours. Bacteremia was defined by positive culture for a recognized pathogen. Receiver operating characteristic (ROC) analyses were performed to determine area under the curve (AUC), sensitivity, and specificity. A multivariable logistic regression model evaluated combined biomarker performance.

Results: Bacteremia occurred in 12 (26.1%) FN episodes. Sepsis, tachycardia, and elevated lactate were more common among bacteremic patients. CRP showed limited early discrimination (AUC 0.62 on day 2) but improved by day 4 (AUC 0.74). PCT was consistently higher in bacteremia (AUC 0.89 at day 4), and lactate demonstrated strong early predictive value (AUC 0.81). CD48 was significantly elevated at 0–24 h (AUC 0.78), outperforming CD64 (AUC 0.60) and preceding CRP rise. In combined modeling, PCT + CD48 + lactate achieved the highest discrimination (AUC 0.92; sensitivity 92%, specificity 85%). Post-hoc power analysis showed 82% power to detect AUC differences ≥0.15.

Conclusion: PCT and CD48 serve as reliable early biomarkers of bacteremia in pediatric FN, with lactate adding metabolic context. Integration of CD48 with PCT and lactate markedly improves diagnostic accuracy, supporting inclusion in future FN risk algorithms to enhance early diagnosis and promote safer antibiotic stewardship.

Downloads

Download data is not yet available.

Citations

Lehrnbecher T, Averbuch D, Castagnola E, Koenig C, Phillips R, Haeusler GM, et al. Guideline for the management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2023 update. J Clin Oncol. 2023;41(9):1873–1890.
Santolaya ME, Alvarez AM, Aviles CL, O’Ryan M, Farfan MJ, Cortes C, et al. Prospective validation of a risk prediction model for invasive bacterial infection in children with febrile neutropenia. Clin Infect Dis. 2020;71(7):1555–1563.
Koenig C, Koenig A, Härtel C, Krueger A, Reinhardt D, Schlapbach LJ, et al. Diagnostics and therapy of paediatric febrile neutropenia: an update. Eur J Pediatr. 2023;182(5):1675–1687.
Wolf J, Bash RO, Wade KC, Flynn PM, Haeusler GM, Lehrnbecher T, et al. Utility of blood cultures in febrile neutropenia: time to positivity and diagnostic yield. Pediatr Blood Cancer. 2021;68(7):e28834.
Haeusler GM, Thursky KA, Slavin MA, Lingaratnam S, Phillips RS, Babl FE, et al. Procalcitonin and C-reactive protein in children with cancer and febrile neutropenia: a systematic review. J Clin Oncol. 2021;39(28):3263–3274.
Doerflinger M, Forsyth C, McCarthy K, Roberts JA, Reuter S, Thompson A, et al. Procalcitonin and IL-10 for early bloodstream infection prediction in febrile neutropenia. Front Immunol. 2021;12:641879.
Urbonas V, Eidukaite A, Tamuliene I. The predictive value of IL-6 and IL-8 in children with febrile neutropenia. J Pediatr Hematol Oncol. 2012;34(2):122–127.
Aquino VM, Cost C, Gomez A, Sandler E, Buchanan GR, Schell MJ, et al. Cytokine and monocyte chemoattractant protein-1 levels in febrile neutropenia. J Pediatr Hematol Oncol. 2012;34(6):e241–e245.
Zaoutis TE, Olsen S, Coffin SE, Keren R, Prosser L, Shah SS, et al. Cytokine variability in pediatric infections: implications for sepsis biomarkers. Infect Control Hosp Epidemiol. 2020;41(6):701–708.
Kitanovski L, Jazbec J, Hojker S, Derganc M, Gvardijančič D, Rajic V, et al. Neutrophil activation markers in pediatric febrile neutropenia. Support Care Cancer. 2014;22(1):269–277.
Sano H, Kobayashi R, Suzuki D, Sano T, Yoshida M, Kobayashi K, et al. Expression of immune activation markers in pediatric febrile neutropenia. Support Care Cancer. 2022;30(3):2141–2149.
Fisher BT, Westling T, Shults J, Harrington WE, Hockenberry MJ, Zaoutis TE, et al. Procalcitonin-guided antimicrobial stewardship in pediatric oncology patients with febrile neutropenia. Pediatr Infect Dis J. 2020;39(10):e317–e323.
Tissières P, Boulkedid R, Nadel S. Procalcitonin in pediatric intensive care decision-making. Ann Intensive Care. 2025;15:22.
Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: mediators, biomarkers, and therapeutic targets. Mediators Inflamm. 2013;2013:165974.
Zakaria M, Salem S, Abdel Rahman M, Fathy M, Omar M, Hassan M, et al. Diagnostic utility of CD64 as an early predictor of infection in febrile neutropenia. Ital J Pediatr. 2025;51:12.
de Almeida Barbosa GG, Rocha AP, Alves JD, Silva MM, Souza CV, Nascimento LP, et al. CD64 expression and blood cultures in febrile neutropenia. Rev Bras Hematol Hemoter. 2015;37(6):387–393.
Hodge G, Osborn M, Hodge S, Holmes M, Reynolds PN, Bryant J, et al. Flow cytometry markers of neutrophil activation in pediatric sepsis. Br J Haematol. 2006;132(2):247–248.
Haeusler GM, Phillips R, Slavin MA, Lingaratnam S, Haeusler LM, Kotecha RS, et al. Recalibration of clinical risk models in febrile neutropenia. EClinicalMedicine. 2020;23:100394.
Sandherr M, Hentrich M, Burchardi D, Vehreschild JJ, Penack O, Buchheidt D, et al. Diagnosis and therapy of febrile neutropenia in adult and pediatric patients: 2025 AGIHO guideline update. Lancet Reg Health Eur. 2025;38:100123.
Cerasi S, Zanin A, D’Angelo P, Palumbo G, Riva C, Santoro C, et al. Presepsin in pediatric febrile neutropenia: diagnostic accuracy and prognostic value. Sci Rep. 2023;13:7078.
Liang J, Wang X, Liu Y, Sun Z, Zhou P, Li M, et al. Prognostic role of presepsin in pediatric febrile neutropenia. Ann Med. 2025;57(1):134–142.
Abdelaziz TA, El Gendy Y, Hussein A, Khalaf M, Ibrahim S, Mahmoud A, et al. Serum lactate as a prognostic marker in pediatric sepsis. BMC Pediatr. 2024;24:199.
Le DTK, Nguyen NT, Tran HT, Doan TT, Pham HT, Vu QN, et al. Lactate/albumin ratio as an outcome predictor in pediatric sepsis. Children (Basel). 2024;11(8):985.

How to Cite



“CD48 AS A NOVEL EARLY BIOMARKER COMPLEMENTING PROCALCITONIN AND LACTATE FOR PREDICTING BACTEREMIA IN PEDIATRIC FEBRILE NEUTROPENIA: A PROSPECTIVE COHORT STUDY: CD48 A NOVEL EARLY BIOMARKER PREDICTING BACTERIEMIA” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026004. doi:10.4084/MJHID.2026.004.